Where Chinese Investors Meet Global Investment News and Opportunities


VolitionRX Ltd (NYSE:VNRX)

Contact Information

VolitionRX Ltd

100 Congress Avenue Austin Texas, 78701
+1 646-650-1351
Scott Powell, Executive Vice President


VolitionRX Ltd. is a New York Stock Exchange listed life sciences company. The company is focused on developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers.

Market Overview

$2.52 (-3.110%)
Vol 79,082.00
10 Days Avg Vol 52,032.56
3 Mo Avg Vol 36,595.34
52 Wk Lo/Hi $2.45 - $5.86
YTD Price Gain % -43.12%
12 Wks Moving Avg 3.372194
200 Days Moving Avg 3.907520
Market Cap 66,827,124

Company Background

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. As cancer screening programs become more and more widespread, our products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. Volition's research and development activities are currently centered in Belgium, with additional offices in London, New York, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.


  • Robust IP portfolio
  • Diagnostic healthcare company with a suite of easy to use blood based cancer diagnostics
  • Potential indication expansion with base platform
  • Current indications include CRC, Lung & Pancreatic
  • Global presence – recently announced Volition America along with Belgian Volition and Singapore Volition
  • Five ongoing clinical trials
  • Anticipated European launch in 2017
  • US Clinical Pathways
  • 510k Trial initiation 2017
  • PMA Trial initiation 2018

Share Structure

VolitionRx Limited
Share Structure
    Common Shares 26.1 million
    Outstanding Options 3 million
    Common Stock Warrants 1.5 million
Fully Diluted Shares 30.6 million
    Board and Management Holdings 25%
Share Trading Activity
    3 month average daily volume(shares) 27,500
    52 week low/high ($/share) $3.05/$5.86
    Current Share Price (Date) $3.39
    Average Warrant Price XX
Market Capitalization (I/O) $88.5 M / $103.7 m
Cash Balance $18.5 m
Debt Outstanding $0.7 m
(all amounts as of March 31, 2017)

Other Information

Research/Products Information

  • Technology, products, and other research highlights
  • Nu.QTM represents a powerful step change in rethinking the approach to cancer.
  • It is a simple solution to the challenging problem of early cancer diagnosis.
  • Nu.QTM unique technology looks for very early ‘nucleosomic’ markers of cancer
  • These tests identify early stage cells before the cancer spreads
  • Nu.QTM uses an array of simple, cost-effective, and accurate blood tests
  • Just a drop of blood

Management Profiles

Cameron Reynolds, MBA

President & CEO

• 20+ years entrepreneurial executive expertise; strong experience in management, structuring and strategic planning of start-up companies • Previous appointments with Integrated Coffee Technologies, Probio, Inc., Mining House Limited • Education: Commerce degree and MBA from The University of Western Australia

Jake Micallef, PhD, MBA


• 20+ years in R&D and management of early stage biotech companies • Previous appointment with World Health Organization, developed diagnostic products in reproductive health and cancer; started Immunometrics Ltd. • Co-founded Gene Expression Technologies, played a major role in procuring GeneICE technology contract with Bayer Pharma • Served as Technical Officer for ValiRx Plc., in-licensed the HyperGenomics and Nucleosomics® technologies and co-founded ValiBio SA., which is now Belgian Volition SA • Education: King’s College London (BSc; PhD); St Thomas’ Hospital Medical School, London (MSc); and Imperial College Management School (MBA)

Scott Powell, PhD

Executive Vice President

• 15+ years experience in investor relations, corporate communication and investment banking • Previous VP of Investor Relations for a NYSE-listed company and SVP with investor relations agency MZ Group; investment banker at Brean Capital, LLC • Education: Bachelor of Science in Business Administration (Finance) from Bryant University and PhD from Brown University